You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ctDNA positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Carcinoma, Gastrointestinal Diseases, Stomach Cancer Trial (Anlotinib HCl capsule, Penpulimab Injection, XELOX)

Not yet recruiting
  • Carcinoma
  • +6 more
  • Anlotinib hydrochloride capsule
  • +2 more
  • (no location specified)
Aug 8, 2022

Stage II Melanoma Trial in United States (Atezolizumab, Tiragolumab, Signatera Assay)

Recruiting
  • Stage II Melanoma
  • Duarte, California
  • +5 more
Nov 10, 2022

Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma Trial in Washington (Atezolizumab, Bevacizumab)

Not yet recruiting
  • Colon Adenocarcinoma
  • +6 more
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Jul 28, 2022

Breast Cancer Trial (Giredestrant, Abemaciclib, Inavolisib)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Feb 1, 2023

ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.

Recruiting
  • Breast Cancer Female
  • +4 more
    • Ho Chi Minh City, Vietnam
    • +1 more
    Oct 16, 2023

    Uveal Melanoma Trial in Pittsburgh (Tebentafusp)

    Not yet recruiting
    • Uveal Melanoma
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Oct 5, 2023

    NSCLC Trial (Almonertinib Envafolimab)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Almonertinib Envafolimab
    • (no location specified)
    Sep 10, 2022

    ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer Trial (Elacestrant, Tamoxifen, Letrozole 2.5mg)

    Not yet recruiting
    • ER-positive Breast Cancer
    • +3 more
    • (no location specified)
    Aug 22, 2022

    Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Seoul (exosome and ctDNA evaluation)

    Active, not recruiting
    • Triple Negative Breast Cancer
    • HER2-positive Breast Cancer
    • exosome and ctDNA evaluation
    • Seoul, Korea, Republic of
      Ji-Yeon Kim
    Jul 13, 2023

    Carcinoma, Non-Small Cell Lung Trial (Atezolizumab, Placebo, Carboplatin)

    Withdrawn
    • Carcinoma, Non-Small Cell Lung
    • (no location specified)
    Jun 14, 2021

    Significance of MRD After Surgery in Driver Gene-positive and

    Enrolling by invitation
    • NSCLC MRD ctDNA
      • Shenzhen, China
        ShenzhenPH
      Jun 30, 2022

      HER2-positive Breast Cancer Trial in Chuo-ku

      Recruiting
      • HER2-positive Breast Cancer
        • Chuo-ku, Tokyo, Japan
          National Cancer Center Hospital, Japan
        Jun 22, 2022

        MRD Test in Common Risk Stage II Colorectal Cancer

        Not yet recruiting
        • Stage II Colorectal Cancer
        • MRD test
        • Xi'an, Shaanxi, China
          First Affiliated Hospital of Xian Jiaotong University
        Mar 29, 2023

        Breast Cancer, Early-Onset Trial in United States (Neoadjuvant chemo administered before surgical extraction of a tumor,

        Active, not recruiting
        • Breast Cancer, Early-Onset
        • Neoadjuvant chemotherapy administered before surgical extraction of a tumor
        • Observational
        • Elizabeth, New Jersey
        • +11 more
        Nov 29, 2022

        Adenocarcinoma of Lung Trial in Beijing (Furmonertinib)

        Not yet recruiting
        • Adenocarcinoma of Lung
        • Beijing, China
          Peking University People's Hospital
        Oct 3, 2021

        HER2 Positive Advanced Gastric Cancer Trial in Beijing (Samples including blood and tissue collection, CTC detection, ctDNA

        Recruiting
        • HER2 Positive Advanced Gastric Cancer
        • Samples including blood and tissue collection
        • +5 more
        • Beijing, Beijing, China
          Beijing Cancer Hospital
        Apr 20, 2022

        Gastrooesophageal Cancer Trial in United Kingdom (Trastuzumab deruxtecan)

        Not yet recruiting
        • Gastrooesophageal Cancer
        • Trastuzumab deruxtecan
        • Southampton, Hampshire, United Kingdom
        • +16 more
        Jul 27, 2023

        NSCLC (NSCLC) Trial (Atezolizumab, RO7198457)

        Withdrawn
        • Non-small Cell Lung Cancer (NSCLC)
        • (no location specified)
        Feb 1, 2021

        Head Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer Trial in United States (other, radiation, diagnostic

        Not yet recruiting
        • Head and Neck Cancer
        • +4 more
        • Experimental Observation
        • +3 more
        • Baltimore, Maryland
        • +5 more
        Oct 16, 2023

        Pancreatic Cancer, Pancreatic Adenocarcinoma Trial in Odense

        Recruiting
        • Pancreatic Cancer
        • Pancreatic Adenocarcinoma
          • Odense, Denmark
            Odense University Hospital
          Jun 5, 2022

          HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Mediated

          Recruiting
          • HPV-Associated Oropharyngeal Squamous Cell Carcinoma
          • +11 more
          • NavDx HPV ctDNA Testing
          • +2 more
          • Boston, Massachusetts
          • +1 more
          Jul 6, 2022

          Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive)

          Recruiting
          • Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
          • +3 more
          • Transoral Surgery
          • +8 more
          • New Brunswick, New Jersey
          • +2 more
          Feb 16, 2022

          Breast Cancer Stage IV Trial in Nice, Villejuif (Alpelisib, Ribociclib)

          Not yet recruiting
          • Breast Cancer Stage IV
          • Nice, France
          • +1 more
          Nov 14, 2022

          Lung Cancer Trial (Almonertinib)

          Not yet recruiting
          • Lung Cancer
          • (no location specified)
          Apr 8, 2021

          Anal Cancer Trial in Worldwide (AMR B: HPV positive ctDNA guided imaging in follow-up)

          Not yet recruiting
          • Anal Cancer
          • AMR B: HPV positive ctDNA guided imaging in follow-up
          • Herlev, Capital Region Of Denmark, Denmark
          • +12 more
          Oct 5, 2022